A Phase 2 interventional study of Paclitaxel and Alisertib in Breast Cancer, Breast Carcinoma and Breast Tumors, sponsored by US Oncology Research. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.
Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Breast Neoplasms by Sarah Cannon Research Institute — none open to participants now, 2 under way, none of them phase 3. Breast Neoplasms · Sarah Cannon Research Institute.
Among the 11 studies in Breast Neoplasms by Sarah Cannon Research Institute, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2015, is one of 8 in phase 2, and was the 8th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 11 studies in Breast Neoplasms by Sarah Cannon Research Institute is open now. The open studies under Breast Neoplasms, anywhere →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 1
First in 2005; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 169 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 10 interventional studies, 14 across the 1 observational. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under US Oncology Research, one of the names counted as Sarah Cannon Research Institute. Under that name alone:
US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Breast Neoplasms by Sarah Cannon Research Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical research study is to learn if the study drug, alisertib (MLN8237), in combination with chemotherapy (paclitaxel), can shrink or slow tumor growth in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative or HR-negative, HER2-negative (triple negative) locally recurrent or metastatic breast cancer (MBC). The safety of alisertib in combination with paclitaxel will also be studied. The physical state of the patient, symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if alisertib plus paclitaxel is safe and effective in patients with this type of breast cancer.
Alisertib belongs to a group of drugs called Aurora kinase inhibitors. Alisertib blocks the activity of Aurora A kinase, a protein that is involved in tumor cell multiplication and survival. Aurora A kinase is expressed at higher than normal levels in many types of cancer, including breast cancer, and preclinical studies suggest that blocking the activity of this protein can lead to the death of cancer cells.
Paclitaxel is a chemotherapy drug commonly used to treat many different kinds of cancer, including metastatic breast cancer. The reason to combine alisertib and paclitaxel is that in cancer therapy, combinations of drugs are often more effective as a treatment than either of the same drugs used alone.
The rationale behind assessing the effectiveness of the addition of alisertib to weekly paclitaxel therapy in patients with Triple Negative Breast Cancer and highly proliferative estrogen receptor-positive (ER+) and HER2- breast cancer is based on the unmet clinical need for effective strategies to prevent or delay resistance to taxane therapy in the metastatic setting. Synergistic or additive effects have been observed in breast cancer xenograft models which involved alisertib added to either paclitaxel or docetaxel. Alisertib inhibited the Pgp-mediated efflux of paclitaxel in a cell culture model. In addition, Aurora Kinase A is frequently overexpressed in Triple Negative Breast Cancer (TNBC), and expression levels have been shown to be prognostic in both of these breast cancer subtypes. The combination of alisertib with paclitaxel has also been investigated in a Phase 1 study in patients with locally advanced or metastatic ovarian and breast cancers, with preliminary evidence of activity in both tumor types including 6 partial response (PR)s and 3 stable disease (SD) in 11 patients with metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subject (≥18 years old), who is either:
or locally recurrent breast cancer with histologic confirmation (on either primary or metastatic tumor) of one of the following:
Exclusion Criteria:
Suspected , untreated brain metastases or current clinical or radiologic progression of known brain metastases or requirement for therapy for brain metastases
More than 1 previous chemotherapy regimen for disease
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
Drug: Paclitaxel
Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg twice a day (BID) on days 1-3, 8-10, and 15-17 of a 28-day cycle
Drug: Paclitaxel · Drug: Alisertib
Paclitaxel 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle
Drug: Paclitaxel
Paclitaxel 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle; Alisertib 40 mg BID on days 1-3, 8-10, and 15-17 of a 28-day cycle
Drug: Paclitaxel · Drug: Alisertib
either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
Also known as: Taxol, Abraxane
40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
Also known as: MLN8237
Time to Disease Progression - Tumor Response Based on RECIST 1.1 Criteria
Measurement of tumors (sum of longest diameters) every 8 weeks for CT/MRI and photographs, and every 12 weeks for bone scan, if applicable. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions (plus an absolute increase of at least 5 mm), or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 3 years from date of patient registration
Overall Survival
Time from randomization to death from any cause
Time frame: up to 4 years from date of patient registration
Between February 2015 and February 2018, a total of 169\* women were enrolled in the trial and were randomly assigned to paclitaxel alone (85 patients), or paclitaxel plus alisertib (84 patients) cohorts. \*174 women were consented and included in baseline demographics. However, 5 of these did not start study treatment due to ineligibility, participant withdrawal, and/or investigator decision, so only 169 participants were included in Participant Flow and AE/SAE analysis.
| Milestone | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib |
|---|---|---|---|---|
| Started | 70 | 66 | 15 | 18 |
| Completed | 36 | 38 | 8 | 10 |
| Not completed | 34 | 28 | 7 | 8 |
| Withdrew: Adverse event | 13 | 14 | 3 | 2 |
| Withdrew: Withdrawal by subject | 9 | 6 | 3 | 2 |
| Withdrew: Physician decision | 4 | 4 | 0 | 2 |
| Withdrew: Other, unrelated complication | 7 | 1 | 1 | 2 |
| Withdrew: Death | 1 | 3 | 0 | 0 |
Measurement of tumors (sum of longest diameters) every 8 weeks for CT/MRI and photographs, and every 12 weeks for bone scan, if applicable. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions (plus an absolute increase of at least 5 mm), or a measurable increase in a non-target lesion, or the appearance of new lesions
| months | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib |
|---|---|---|---|---|
| Time to Disease Progression - Tumor Response Based on RECIST 1.1 Criteria | 7.1 (3.8 to 10.6) | 10.2 (3.8 to 15.7) | 5.7 (2.9 to 8.2) | 9.6 (6.1 to 22.6) |
Time from randomization to death from any cause
| months | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib |
|---|---|---|---|---|
| Overall Survival | 25.1 (16.0 to 30.5) | 26.3 (18.7 to 37.2) | 12.7 (6.8 to 23.5) | 16.0 (9.6 to 34.0) |
Collected over until 30 days after last dose of patient's study treatment, for up to 2 years from date of registration (enrollment into study). However, mortality data was collected for up to 4 years from date of registration.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ER+/HER2- Paclitaxel Alone | 43/70 (61.4%) | 2/70 (2.9%) | 69/70 (98.6%) |
| ER+/HER2- Paclitaxel Plus Alisertib | 39/69 (56.5%) | 13/66 (19.7%) | 65/66 (98.5%) |
| Triple Negative Paclitaxel Alone | 14/16 (87.5%) | 0/15 (0%) | 15/15 (100%) |
| Triple Negative Paclitaxel Plus Alisertib | 13/19 (68.4%) | 6/18 (33.3%) | 18/18 (100%) |
| Event | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib |
|---|---|---|---|---|
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/70 | 1/66 | 0/15 | 2/18 |
| SEPSISInfections and infestations | 0/70 | 1/66 | 0/15 | 2/18 |
| DIARRHEAGastrointestinal disorders | 0/70 | 3/66 | 0/15 | 1/18 |
| INFECTION FUNGALInfections and infestations | 0/70 | 0/66 | 0/15 | 1/18 |
| NEUTROPENIABlood and lymphatic system disorders | 1/70 | 2/66 | 0/15 | 0/18 |
| NAUSEAGastrointestinal disorders | 0/70 | 1/66 | 0/15 | 0/18 |
| CHEST PAINGeneral disorders | 0/70 | 1/66 | 0/15 | 0/18 |
| NEUROPATHY PERIPHERALNervous system disorders | 0/70 | 1/66 | 0/15 | 0/18 |
| EMBOLISM PULMONARYRespiratory, thoracic and mediastinal disorders | 0/70 | 1/66 | 0/15 | 0/18 |
| INFECTION RESPIRATORYRespiratory, thoracic and mediastinal disorders | 0/70 | 1/66 | 0/15 | 0/18 |
| Event | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib |
|---|---|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 13/70 | 43/66 | 5/15 | 14/18 |
| DIARRHEAGastrointestinal disorders | 7/70 | 39/66 | 4/15 | 9/18 |
| FATIGUEGeneral disorders | 27/70 | 33/66 | 7/15 | 9/18 |
| ALOPECIASkin and subcutaneous tissue disorders | 31/70 | 31/66 | 4/15 | 4/18 |
| NAUSEAGastrointestinal disorders | 18/70 | 28/66 | 6/15 | 7/18 |
| ANEMIABlood and lymphatic system disorders | 6/70 | 16/66 | 5/15 | 6/18 |
| CONSTIPATIONGastrointestinal disorders | 11/70 | 7/66 | 3/15 | 6/18 |
| MUCOSITIS ORALGastrointestinal disorders | 3/70 | 19/66 | 1/15 | 4/18 |
| HEADACHENervous system disorders | 3/70 | 6/66 | 2/15 | 5/18 |
| NEUROPATHY PERIPHERALNervous system disorders | 12/70 | 4/66 | 4/15 | 1/18 |
174 participants were consented and included in baseline analysis. However, 5 of these did not start study treatment due to ineligibility, participant withdrawal, and/or investigator decision, so only 169 participants were included in Participant Flow and Adverse Event/Serious Adverse Event (AE/SAE) Analysis.
| Age, Categorical(Participants) | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 31 | 4 | 6 | 66 |
| >=65 years | 45 | 38 | 12 | 13 | 108 |
| Age, Continuous(years) | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib | Total |
|---|---|---|---|---|---|
| Median | 63.2 (26.9 to 84.2) | 62.5 (33.1 to 83.4) | 65.2 (53.1 to 81.3) | 63.2 (38.8 to 75.0) | 63.2 (26.9 to 84.2) |
| Sex: Female, Male(Participants) | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib | Total |
|---|---|---|---|---|---|
| Female | 70 | 69 | 16 | 19 | 174 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib | Total |
|---|---|---|---|---|---|
| Asian | 1 | 1 | 1 | 0 | 3 |
| Black | 6 | 7 | 6 | 4 | 23 |
| Caucasian | 55 | 54 | 9 | 13 | 131 |
| Hispanic | 6 | 6 | 0 | 2 | 14 |
| Other | 2 | 1 | 0 | 0 | 3 |
| Region of Enrollment(Participants) | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib | Total |
|---|---|---|---|---|---|
| United States | 70 | 69 | 16 | 19 | 174 |
| Positive Nodes(Participants) | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib | Total |
|---|---|---|---|---|---|
| 0 | 36 | 33 | 7 | 9 | 85 |
| 1-3 | 20 | 20 | 3 | 4 | 47 |
| 4 or more | 9 | 13 | 5 | 5 | 32 |
| Missing | 5 | 3 | 1 | 1 | 10 |
| Prior Chemotherapy for Metastatic Disease(Participants) | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib | Total |
|---|---|---|---|---|---|
| No prior chemotherapy | 48 | 48 | 11 | 13 | 120 |
| 1 prior chemotherapy | 22 | 21 | 5 | 6 | 54 |
| Current Histology(Participants) | ER+/HER2- Paclitaxel Alone | ER+/HER2- Paclitaxel Plus Alisertib | Triple Negative Paclitaxel Alone | Triple Negative Paclitaxel Plus Alisertib | Total |
|---|---|---|---|---|---|
| Ductal | 47 | 45 | 11 | 16 | 119 |
| Lobular | 10 | 9 | 1 | 0 | 20 |
| Mixed DL | 2 | 2 | 0 | 0 | 4 |
| Other | 11 | 13 | 4 | 2 | 30 |
| Missing | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Apr 2024, 109 months.
Results were first posted in Oct 2024, 5 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 109 months is above that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLN 8237